GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway-Reference-Cited by-同舟云学术

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Published:2011-10-13 Issue:12 Volume:10 Page:2426-2436
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Wallin Jeffrey J.,Edgar Kyle A.,Guan Jane,Berry Megan,Prior Wei Wei,Lee Leslie,Lesnick John D.,Lewis Cristina,Nonomiya Jim,Pang Jodie,Salphati Laurent,Olivero Alan G.,Sutherlin Daniel P.,O'Brien Carol,Spoerke Jill M.,Patel Sonal,Lensun Letitia,Kassees Robert,Ross Leanne,Lackner Mark R.,Sampath Deepak,Belvin Marcia,Friedman Lori S.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 208 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

2. ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells;International Journal of Molecular Sciences;2024-05-09

3. Retrospective Assessment of Translational Pharmacokinetic–Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor;Drugs in R&D;2024-05-03

4. Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure‐Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor);The Journal of Clinical Pharmacology;2024-04-19

5. Design of PI3K-mTOR Dual Inhibitors for Ovarian Cancer: Are We on the Right Track?;Current Medicinal Chemistry;2024-04-04